Physician profile

Odrick Roberto Rosas

Physical Medicine & Rehabilitation · Toa Alta, PR

NPI 1477940500

$1,025.98

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

See the full distribution for Physical Medicine & Rehabilitation

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$124.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $248.02 2021-2023 Farxiga
Janssen Pharmaceuticals, INC $239.50 2019-2020
Ferring Pharmaceuticals INC. $125.00 2019
Sanofi-Aventis U.S. LLC $100.00 2019
Tanabe Pharma America, INC. $95.65 2019
Merck Sharp & Dohme LLC $77.91 2019
Bard Peripheral Vascular, INC. $71.21 2022
Pfizer Pharmaceuticals LLC $29.36 2019
Ptc Therapeutics, INC. $28.10 2019
Abbvie INC. $11.23 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Odrick Roberto Rosas

$1,025.98

in general payments reported 2019-2025

Years
2019-2023
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/2774258/odrick-roberto-rosas

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.